申请人:Zeneca Limited
公开号:US05985281A1
公开(公告)日:1999-11-16
A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.
用于治疗宿主的双组分系统,第一组分包括能够与肿瘤相关抗原结合的靶向基团,与一个能够将前体药物转化为抗肿瘤药物的突变酶相连,第二组分包括一个在受突变酶影响下可转化为抗肿瘤药物的前体药物。该突变酶是一种天然宿主酶的突变形式,通过与底物的离子对相互作用识别其天然底物,其中突变酶和前体药物的结构使得突变酶/前体药物离子对相互作用的极性相对于天然宿主酶/天然底物离子对相互作用被颠倒。第一组分在宿主中基本上不具有免疫原性,而前体药物第二组分在宿主中不会通过天然未突变的宿主酶显著转化为抗肿瘤药物。